Scientist II, Translational Science
ModeX Therapeutics
Summary
ModeX Therapeutics is seeking a highly skilled and motivated Scientist II to support the development and execution of biomarker strategies across early-stage clinical programs. The successful candidate will contribute to the design, implementation, and interpretation of biomarker studies that inform mechanism of action, patient selection, pharmacodynamic activity, and clinical development decisions.
Job description
The position requires previous experience in Immuno-Oncology and multi-parameter flow cytometry analysis; experience in Clinical Biomarkers is preferred. Key responsibilities include analyzing biomarker data from several clinical studies, updating and managing biomarker datasets, and carrying out translational in vitro studies to support biomarker discovery and method development.
Key Responsibilities
- Support the development and execution of clinical biomarker plans for ModeX's clinical studies.
- Contribute to the selection, validation, and implementation of biomarker assays, including flow cytometry, immunophenotyping, cytokine analyses, soluble biomarkers, genomics, transcriptomics, and tissue-based assays.
- Monitor biomarker sample quality, assay performance, and data delivery timelines.
- Manage activities and deliverables of external laboratories, CROs, and academic collaborators.
- Perform biomarker data review, analysis, interpretation, and visualization to support study objectives and decision-making.
- Integrate biomarker, clinical, pharmacokinetic (PK), and safety data to generate biological insights.
- Prepare biomarker data summaries, reports, presentations, and study team updates.
- Maintain awareness of emerging biomarker technologies, therapeutic area trends, and translational research advances.
- Perform translational science studies to support IND-enabling studies, accelerate biomarker discovery, and contribute to the advancement of various preclinical and clinical programs.
Qualifications
- PhD in Immunology or a related field
- 2 – 5+ years of highly relevant work experience in Immunology, preferably Immuno-Oncology and T cell biology, with good track record from industry or academia
- Experience supporting biomarker activities in clinical development is preferred.
- Hands-on experience in immune cell assays and multi-parameter flow cytometry. Experience with antibody-based therapeutics is a plus
- Ability to interpret and communicate complex biological datasets.
- Proficiency with data analysis and visualization tools (e.g., GraphPad Prism, R)
- Good written and oral communication, organizational skills, and experience in data generation/analysis.
- Outstanding learning ability, troubleshooting and problem-solving skills
- Highly adaptable to a fast-paced working environment and capable of working effectively in a team setting as well as individually
Requirements
- PhD in Immunology or a related field
- 2 – 5+ years of highly relevant work experience in Immunology, preferably Immuno-Oncology and T cell biology
- Hands-on experience in immune cell assays and multi-parameter flow cytometry
- Ability to interpret and communicate complex biological datasets
- Proficiency with data analysis and visualization tools (e.g., GraphPad Prism, R)
- Good written and oral communication and organizational skills
- Outstanding learning ability, troubleshooting and problem-solving skills
- Highly adaptable to a fast-paced working environment and capable of working in a team setting as well as individually
Company overview
ModeX Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative multispecific biologics for cancer and infectious diseases. Founded in 2020 by eminent medical innovators including Gary Nabel and Elias Zerhouni, the company operates as a wholly owned subsidiary of OPKO Health. ModeX's proprietary platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency against complex diseases. The company's MSTAR (Synergistic Targeting of Antigens and Receptors) platform enables the development of multispecific antibodies that can engage multiple targets simultaneously, offering enhanced therapeutic efficacy. ModeX's pipeline includes candidates targeting both solid and liquid tumors, as well as several of the world's most pressing viral threats including HIV, COVID-19, and Epstein-Barr virus. The company has established strategic collaborations with industry leaders such as Regeneron and Merck, and has secured significant funding from BARDA for infectious disease programs. Based in Weston, Massachusetts, ModeX employs approximately 51-200 professionals and has advanced multiple candidates into clinical trials, positioning itself as a leader in next-generation multispecific biologic development.